On May 25th, Hengrui Medicine announced that it had received the "Drug Supplementary Application Approval Notice" approved and issued by the National Medical Products Administration, approving the company's paricalcitol injection to pass the quality and efficacy consistency evaluation of generic drugs. The first company to be reviewed. The approved indication is for the treatment of secondary hyperparathyroidism in patients with chronic renal failure undergoing hemodialysis.

Paricalcitol is a synthetic vitamin D analogue with biological activity, modified on the side chain (D2) and A ring (19-nor) of calcitriol. Vitamin D and paricalcitol can reduce the level of PTH by inhibiting the synthesis and secretion of parathyroid hormone (PTH). Compared with existing treatment programs, Paricalcitol has obvious advantages in accuracy and safety, and it is expected to bring good news to more hemodialysis patients.